PETS on Nasdaq

PetMed Express

Logo: PetMed Express, Public domain, via Wikimedia Commons5

American online pet pharmacy

PetMed Express, Inc., also known as PetMeds, is an online pet pharmacy based in the United States. It is publicly traded and sells prescription and non-prescription pet medication.3 Its shares trade on Nasdaq under the symbol PETS.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

$179.0MRevenue, fiscal 20266
-$57.3MNet income, fiscal 20266
1996Founded1

Compare with Ridgetech Inc., Guardian Pharmacy Services, Inc. or TREES Corp (Colorado), or pick any stock.

  • TickerPETS on Nasdaq1
  • Industryveterinary medicine1
  • HeadquartersPompano Beach1
  • Websitewww.1800petmeds.com
  • Incorporated inFL7
  • Business address420 South Congress Avenue, Delray Beach, Fl 334457
  • Filer categoryNon-accelerated filer, Smaller reporting company7
  • Legal formCorporation4
  • LEI529900PGHW5ASJ1AZL484
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered address420 South Congress Avenue, 33445 Delray Beach, United States4
  • Registered withFlorida Division of Corporations, P960000100984

PetMed Express, Inc., also known as PetMeds, is an online pet pharmacy based in the United States. It is publicly traded and sells prescription and non-prescription pet medication.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

28.1%Gross margin6
-32.8%Operating margin6
-32.0%Net margin6
-21.1%Revenue growth, 20266
-197.9%Return on equity6
-$33.0MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Other costs100¢$178.9M
  • Income tax0¢$73.0K

Out of $179.0M in revenue.6 The company lost money this year.

Financial statements

Revenue9101112136$179.0M in 2026−37% since 2019
0$100.0M$200.0M$300.0M$400.0M2019: $283.4M$283.4M20192020: $284.1M$284.1M2020+0%2021: $303.6M$303.6M2021+7%2022: $272.3M$272.3M2022−10%2023: $247.6M$247.6M2023−9%2024: $274.1M$274.1M2024+11%2025: $227.0M$227.0M2025−17%2026: $179.0M$179.0M2026−21%
Gross profit9101112136$50.2M in 2026−47% since 2019
0$25.0M$50.0M$75.0M$100.0M2019: $95.3M$95.3M20192020: $81.2M$81.2M2020−15%2021: $84.3M$84.3M2021+4%2022: $76.9M$76.9M2022−9%2023: $76.5M$76.5M2023−1%2024: $84.8M$84.8M2024+11%2025: $69.1M$69.1M2025−18%2026: $50.2M$50.2M2026−27%
Operating income9101112136-$58.7M in 2026
-$100.0M-$50.0M0$50.0M2019: $46.2M$46.2M20192020: $31.0M$31.0M2020−33%2021: $30.5M$30.5M2021−1%2022: $24.3M$24.3M2022−20%2023: $6.1M$6.1M2023−75%2024: -$8.2M-$8.2M20242025: -$1.5M-$1.5M2025−81%2026: -$58.7M-$58.7M2026+3735%
Net income9101112136-$57.3M in 2026
-$75.0M-$50.0M-$25.0M0$25.0M$50.0M2019: $37.7M$37.7M20192020: $25.9M$25.9M2020−32%2021: $23.9M$23.9M2021−7%2022: $18.7M$18.7M2022−22%2023: $5.1M$5.1M2023−73%2024: -$7.5M-$7.5M20242025: -$6.3M-$6.3M2025−16%2026: -$57.3M-$57.3M2026+814%

Every line of the income statement as filed: the last 3 fiscal years, latest first.6

Period ending2026-03-312025-03-312024-03-31
Net sales$179.0M$227.0M$274.1M
Cost of sales$126.7M$157.8M$189.3M
Inventory write-down$2.1M$0$0
Gross profit$50.2M$69.1M$84.8M
General and administrative$50.7M$38.6M$55.2M
Advertising$21.5M$23.8M$30.6M
Depreciation and amortization$9.4M$7.0M$7.1M
Impairment of goodwill and intangible assets$27.3M$1.2M$0
Total operating expenses$108.9M$70.7M$92.9M
Loss from operations-$58.7M-$1.5M-$8.2M
Interest income (expense), net$511.0K$185.0K$511.0K
Other, net$803.0K$758.0K$1.4M
Total other income (expense)$1.3M$943.0K$1.9M
(Loss) income before provision for income taxes-$57.4M-$587.0K-$6.3M
(Benefit) provision for income taxes-$73.0K$5.7M$1.2M
Net loss-$57.3M-$6.3M-$7.5M
Basic (in dollars per share)-$2.74-$0.30-$0.37
Diluted (in dollars per share)-$2.74-$0.30-$0.37
Basic (in shares)20.9M shares20.6M shares20.4M shares
Diluted (in shares)20.9M shares20.6M shares20.4M shares
Cash dividends declared per common share (in dollars per share)$0.00$0.00$0.60

Compare PetMed Express with another company

Corporate structure

PetMed Express sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of PetMed Express

  • PetMed Express Delray Beach, Florida, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What PetMed Express reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$58.2M6 Mar 31, 2026$54.1M6 Mar 31, 2025+7.7%
Accumulated depreciation$31.9M6 Mar 31, 2026$25.2M6 Mar 31, 2025+26.6%
Property and equipment, net$26.3M6 Mar 31, 2026$28.9M6 Mar 31, 2025−8.8%
Operating-lease assets (leased space)$512.0K6 Mar 31, 2026$966.0K6 Mar 31, 2025−47.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$21.4M6 Mar 31, 2026$54.7M6 Mar 31, 2025−60.9%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$06 Mar 31, 2026$26.7M6 Mar 31, 2025−100.0%
Intangible assets, net (excluding goodwill)$5.5M6 Mar 31, 2026$8.0M6 Mar 31, 2025−31.8%
Accumulated amortization$5.9M6 Mar 31, 2026$3.9M6 Mar 31, 2025+50.0%
Finite-lived intangibles, net$5.8M13 Mar 31, 2025$7.7M12 Mar 31, 2024−25.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$13.6M6 Mar 31, 2026$16.2M6 Mar 31, 2025−16.0%

Properties, in its own words

We own our principal executive offices and distribution center, which are located at 420 South Congress Avenue, Delray Beach, Florida 33445 (the “Delray Beach Property”). The Delray Beach Property consists of approximately 557,000 square feet of land or 12.83 acres with two building complexes totaling approximately 185,000 square feet, with additional land for future use. The first building complex consists of approximately 125,000 square feet and the second building complex consists of approximately 60,000 square feet each consisting of both office and warehouse space. The Company occupies approximately 97,000 square feet of the first building for its principal offices and distribution center. As

of March 31, 2026, 39% of the Delray Beach Property was leased to two tenants with a remaining weighted average lease term of 4.3 years. We believe that our facilities are sufficient for our current needs and are in good condition in all material respects.

The rest of Item 2

In connection with our acquisition of PetCareRx, in April 2023 we assumed the leases of two buildings occupied by PetCareRx located in Lynbrook, New York. These facilities, which aggregate approximately 32,000 square feet, are used by PetCareRx as a shipping and fulfillment center and as an executive office. The leases expire in April 2027 and include the option to renew for an additional five years.

Item 2 of the 10-K filed Jun 2, 2026.18

The story

Petmed Express was founded in Florida in 1996 by Marc Puleo. Puleo was an anesthesiologist who wanted to open a mail-order business for human prescriptions that also sold pet accessories. He shifted his focus to pet medicines due to Merck already heavily controlling the human prescription market. The company initially grew through word of mouth, television commercials, and its catalogs.

Its stock was traded on the OTC Bulletin Board under the symbol PETS from September 1997 until March 2000; in March 2000 the company began the process of becoming listed on the National Quotation Bureau Electronic Quotation Service and became responsible for reporting to the SEC.

Until 2002 PetMed Express and a company called Savemax Inc. operated in the same premises, shared staff, and operated under the same pharmacy licenses. According to the lawyer for both companies, Savemax was formed because of "a concern over PetMed's liability, and whether it [would] continue." From 1999 to 2002, PetMed Express and SaveMax were charged with violating the pharmaceutical law in several states. In one instance it was fined by the Environmental Protection Agency for selling drugs in metric doses, and has also received a warning letter from the FDA for selling misbranded drugs. In 1999, PetMed Express settled charges with the Florida Pharmacy Board for selling drugs that did not have prescriptions, false advertising, poor record keeping, and not labelling drugs correctly.

In addition to pet medications, PetMed Express also sold pet accessories such as leashes. In 2000, Tricon Holdings invested $2 million into the company. The company also hired Menderes Akdag as CEO in 2001. It discontinued 5,000 products and began focusing strictly on medicine-related items.

In 2002, PetMed Express and Savemax were fined by the EPA for selling prescription drugs illegally. The drugs were made by Novartis for sale in Europe and Australia and the doses and labelling were not FDA-approved. Also in 2002, PetMed Express, this time with Savemax, the company reached a settlement with the Florida Pharmacy Board for contracting with veterinarians to write prescriptions for animals they had never examined. The Florida board provided information to national boards and encouraged other state boards to take actions against veterinarians who had worked with PetMed Express to provide prescriptions for animals they had not examined. In the same year, the company settled similar charges in Ohio. In November 2002, the pharmacy board in Texas filed a lawsuit charging PetMed Express with dispensing veterinary drugs without prescriptions. The case was settled in 2006 with a $50,000 fine and three years' probation.

In 2004 a securities class action lawsuit was filed against the company, claiming that the company was not candid about the difficulty in getting prescriptions authorized by veterinarians. In 2005, the lawsuits were voluntarily dismissed by the plaintiffs. Puleo stepped down from executive leadership with the company the same year. Another shareholder lawsuit was filed against the company in 2018, claiming that it marketed dangerous animal drugs to humans. The lawsuit was later dismissed by plaintiffs after investigation of the claims.

As announced by PetMed Express Inc. in a regulatory filing published on Friday, June 4, 2021, Menderes Akdag, chief executive officer, leaves the online pet pharmacy after around 20 years in the role. PetMed said: “On May 28, 2021, the Board of Directors of PetMed Express, Inc. (the “Company”) notified Menderes Akdag, President and Chief Executive Officer, that the Company will not extend Mr. Akdag’s employment agreement with the Company and that the employment agreement would therefore end on July 30, 2021 in accordance with the scheduled end date of the agreement. The Company has presented a proposal to Mr. Akdag regarding the continuation of his role as President and Chief Executive Officer for a transition period following July 30, 2021 until a new CEO is appointed.” Matthew N. Hulett, the former president of language learning giant Rosetta Stone, was named CEO and president effective August 30, 2021. Hulett entered into a three-year employment agreement with PetMed Express at a $500,000 base salary per year. He also received 90,000 shares of restricted stock and 510,000 shares of performance restricted stock.

In April 2022, the company signed a partnership with Vetster, a telehealth veterinary company. As part of the agreement, PetMeds will be the exclusive eCommerce provider of Vetster medications, and Vetster will be the exclusive provider of telehealth services to PetMeds customers.

Read the full text

In 2023, PetMed partnered with Pumpkin Pet Insurance a pet insurance provider. In 2025, PetMed launched PetHealthMD a pet care insurance provider.

From Wikipedia’s article on PetMed Express, shared under CC BY-SA 4.0.8

Leadership

Who has led PetMed Express, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (18)

Products and brands

  • veterinary drug

Listed on Wikidata.1

PetMed Express is an online pharmacy that sells prescription and non-prescription pet medication and nutritional supplements. It can only fill prescriptions written by veterinarians, and competes with veterinarians who derive some of their income from selling pet medication.

From Wikipedia’s article on PetMed Express, shared under CC BY-SA 4.0.8

Timeline

  1. Sep 29, 2026New chief executive Jeffrey Allen Willard becomes CEO19
  2. Sep 28, 20268-K Executive or director change42
  3. Sep 21, 20268-K Executive or director change; Regulation FD disclosure43
  4. Sep 17, 20268-K Executive or director change; Regulation FD disclosure44
  5. Aug 13, 20268-K Results of operations45
  6. Aug 12, 20268-K Executive or director change; Shareholder vote46
  7. Jul 23, 20268-K Entered a material agreement; Regulation FD disclosure47
  8. Jun 26, 20268-K Executive or director change48
  9. Jun 2, 20268-K Results of operations49
  10. May 21, 20268-K Director nominations50
  11. Jan 23, 20268-K Shareholder vote51
  12. Dec 29, 20258-K Change of auditor52
  13. Dec 9, 20258-K Change of auditor53
  14. May 1, 2024New chief executive Sandra Yvette Campos becomes CEO20
  15. Aug 31, 2021New chief executive Mathew N. Hulett becomes CEO21
  16. Jan 24, 2006New chief executive Menderes Akdag becomes CEO22
  17. 1996Founded Founded1

Calendar

Coming up

  1. Around Oct 24, 2026Next results, estimated About a quarter after its last report. The company hasn't announced the date.

When it reported results

  1. Aug 13, 2026Reported quarterly or annual results45
  2. Jun 2, 2026Reported quarterly or annual results49
  3. Nov 13, 2025Reported quarterly or annual results54
  4. Oct 14, 2025Reported quarterly or annual results55
  5. Jun 16, 2025Reported quarterly or annual results56
  6. Feb 10, 2025Reported quarterly or annual results57
  7. Nov 6, 2024Reported quarterly or annual results58
  8. Aug 6, 2024Reported quarterly or annual results59

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

244 filings to the SEC since October 2021: 6 annual reports, 17 quarterly reports, 77 major events, 93 insider forms, 24 large holders, 27 other. The latest 20:

  1. Sep 29, 20264 EDGAR
  2. Sep 29, 20263 EDGAR
  3. Sep 28, 2026S-8 EDGAR
  4. Sep 28, 2026S-8 EDGAR
  5. Sep 28, 20268-K EDGAR
  6. Sep 21, 20264 EDGAR
  7. Sep 21, 20263 EDGAR
  8. Sep 21, 20268-K EDGAR
  9. Sep 17, 20268-K EDGAR
  10. Aug 13, 20264 EDGAR
  11. Aug 13, 202610-Q EDGAR
  12. Aug 13, 20268-K EDGAR
  13. Aug 13, 2026SCHEDULE 13G/A EDGAR
  14. Aug 12, 20264 EDGAR
  15. Aug 12, 20264 EDGAR
  16. Aug 12, 20268-K EDGAR
  17. Aug 12, 20264 EDGAR
  18. Jul 24, 20264/A EDGAR
  19. Jul 23, 20268-K EDGAR
  20. Jun 29, 2026SCHEDULE 13D/A EDGAR

The 244 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

28 open-market trades by officers, directors and large owners since October 2021: 26 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 8, 2026MATZ ZYMAN STEPHANNIE10% ownerBuy25,000$1.75$43.8KForm 4
Aug 13, 2025Silvercape Investments Ltd10% ownerBuy101,000$3.17$320.2KForm 4
Aug 1, 2025Silvercape Investments Ltd10% ownerBuy118,200$3.21$379.4KForm 4
Jul 21, 2025TACHE GALANTE MOISES10% ownerBuy25,000$3.50$87.5KForm 4
Jul 18, 2025Silvercape Investments Ltd10% ownerBuy17,565$3.23$56.7KForm 4
Jul 17, 2025Silvercape Investments Ltd10% ownerBuy31,701$3.15$99.9KForm 4
Jul 2, 2025Silvercape Investments Ltd10% ownerBuy2,817$3.22$9.1KForm 4
Jul 1, 2025Silvercape Investments Ltd10% ownerBuy694$3.21$2.2KForm 4
Jun 3, 2025MATZ ZYMAN STEPHANNIE10% ownerBuy25,000$3.94$98.5KForm 4
May 21, 2025NINA CAPITAL HOLDINGS INC.10% ownerBuy25,000$3.86$96.5KForm 4
May 20, 2025Silvercape Investments Ltd10% ownerBuy7,401$3.95$29.2KForm 4
Apr 30, 2025Campos Sandra YvetteCEO & PresidentSale60,463$3.31$200.2KForm 4
Mar 18, 2025MATZ ZYMAN STEPHANNIE10% ownerBuy100,000$4.09$409.0KForm 4
Mar 10, 2025MATZ ZYMAN STEPHANNIE10% ownerBuy100,000$4.11$411.0KForm 4
Mar 3, 2025MATZ ZYMAN STEPHANNIE10% ownerBuy50,000$4.33$216.5KForm 4
Feb 3, 2025MATZ ZYMAN STEPHANNIE10% ownerBuy25,000$4.82$120.5KForm 4
Jan 27, 2025TACHE GALANTE MOISES10% ownerBuy25,000$4.64$116.0KForm 4
Jan 24, 2025TACHE GALANTE MOISES10% ownerBuy25,000$4.95$123.8KForm 4
Jan 7, 2025MATZ ZYMAN STEPHANNIE10% ownerBuy25,000$4.98$124.5KForm 4
Dec 16, 2024TACHE GALANTE MOISES10% ownerBuy32,000$5.66$181.1KForm 4

All 28 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2026Leslie CampbellInterim Chief Executive Officer and President67$815.8K$830.2K68
2026Sandra CamposFormer Chief Executive Officer and President$224.2K$683.8K68
2026Robyn D’EliaFormer Chief Financial Officer$173.3K$511.4K68
2026Douglas KrulikChief Accounting Officer57$316.2K$426.8K68
2025Sandra CamposFormer Chief Executive Officer and President$497.0K$3.9M68
2025Robyn D’EliaFormer Chief Financial Officer$212.5K$1.1M68
2025Douglas KrulikChief Accounting Officer57$173.1K$336.7K68
2025Leslie CampbellInterim Chief Executive Officer and President67$53.8K$78.2K68

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 50. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Renaissance Technologies LLC1,131,230$2.2M0.0%−55,139
Vanguard Capital Management LLC827,397$1.6M0.0%−4,034
BlackRock, Inc.568,255$1.1M0.0%+16,578
Federated Hermes, Inc.212,170$407.4K0.0%−454,635
Geode Capital Management, LLC204,075$391.9K0.0%−17,447
Steel Partners Holdings L.P.193,664$371.8K0.5%No change
UBS Group AG138,330$265.6K0.0%−95,346
Bridgeway Capital Management, LLC121,048$232.4K0.0%−11,676
Rangeley Capital, LLC121,000$232.3K0.2%+11,792
Vanguard Fiduciary Trust Co110,481$212.1K0.0%+769
State Street Corp105,173$201.9K0.0%No change
Formidable Asset Management, LLC85,551$195.1K0.0%−19,650
Empowered Funds, LLC82,348$158.1K0.0%+7,324
Tudor Investment Corp Et Al81,407$156.3K0.0%New
Arrowstreet Capital, Limited Partnership79,503$152.6K0.0%−47,271
Citadel Advisors LLC74,127$142.3K0.0%−13,767
Dimensional Fund Advisors LP60,353$115.8K0.0%−147,416
UMB Bank, n.a.60,000$115.2K0.0%No change
Susquehanna International Group, Llp47,733$91.6K0.0%New
Northern Trust Corp42,653$81.9K0.0%−4,421
XTX Topco Ltd41,933$80.5K0.0%New
Simplex Trading, LLC24,845$47.7K0.0%New
IMC-Chicago, LLC22,924$44.0K0.0%New
Jain Global LLC13,619$26.1K0.0%New
American Century Companies Inc12,871$24.7K0.0%−9,832

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How PetMed Express is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPETMED EXPRESS INC2
  • CIK0001040130
  • Employer ID (EIN)65-068096718
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company18
  • Incorporated inFlorida18
  • Fiscal year endsMarch 312
  • Industry code (SIC)5912 Retail-Drug Stores and Proprietary Stores2
  • SEC reviewing officeOffice of Trade & Services, Division of Corporation Finance2
  • Business address420 South Congress Avenue, Delray Beach, FL 334452
  • Phone(561) 426-44442
  • Shares outstanding21,678,914 as of Aug 7, 202616
  • Public float$46.0M as of Sep 30, 202518
  • AuditorRSM US LLP, Coral Gables, Florida PCAOB ID 23; no auditor attestation of internal control over financial reporting18
  • On EDGAR sinceJan 10, 20002
  • Filings1,235 in all: 4 (486), 8-K (387), SC 13G/A (71), 10-Q (70), SC 13G (32), 3 (29), 10-K (23), DEF 14A (23)2
    All 40 form types

    4/A (15), DEFA14A (11), 10QSB (9), S-8 (9), CORRESP (8), UPLOAD (7), 424B3 (6), NT 10-Q (5), S-8 POS (5), 10KSB (4), 8-K/A (4), SCHEDULE 13G/A (4), NT 10-K (3), 10-Q/A (2), 10SB12G/A (2), PRE 14A (2), SCHEDULE 13D (2), SCHEDULE 13D/A (2), 10-K/A (1), 10QSB/A (1), 10SB12G (1), 5 (1), 8-A12B (1), 8-A12B/A (1), DEF 14C (1), DEFR14A (1), POS AM (1), PRE 14C (1), S-1/A (1), SB-2 (1), SC 14F1 (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Jun 2, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) Jun 25, 2026
    Latest 8-K (8-K) Sep 28, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, PETS $.001 Par value per sharePETSNASDAQ
Preferred Stock Purchase RightsNASDAQ

From the cover page of the 10-K filed Jun 2, 2026 (Section 12(b) of the Exchange Act).18

Risk factors and legal proceedings

The risks PetMed Express names in Item 1A of its 10-K filed Jun 2, 2026: 37 risks under these headings, as written.18

  • Regulatory Risks
  • Any failure to comply with various state or federal regulations covering our pet health business, including the dispensing of prescription pet medications may subject us to reprimands, sanctions, probations, fines, suspensions, or the loss of one or more of our pharmacy licenses.
  • Business Risks
  • Our failure to properly manage our inventory may result in excessive inventory carrying costs, or inadequate supply of products, which could materially adversely affect our financial condition and results of operations.
  • Resistance from veterinarians to authorize prescriptions, or attempts or efforts by veterinarians to discourage pet owners from purchasing from us could cause our sales to decrease and could materially adversely affect our financial condition and results of operations.
  • Significant portions of our sales are made to residents of eight states. If we should lose our pharmacy license in one or more of these states, our financial condition and results of operations would be materially adversely affected.
  • We have direct buying relationships with major pet medication manufacturers and distributors each contractual relationship depends on our compliance with each respective manufacturer’s minimum advertised pricing policies (MAPP).
  • The loss of any of our key suppliers would negatively impact our business.
  • Shipping is a critical part of our business and any changes in, or disruptions to, our shipping arrangements could adversely affect our business, financial condition, and results of operations.
  • The quality of our customer service and support is important to our customers, and if we fail to provide adequate levels of customer service and support, we could lose customers, which would harm our business.
  • The content of our websites could expose us to various kinds of liability, which, if prosecuted successfully, could negatively impact our business.
  • We may not be able to protect our intellectual property rights, and/or we may be found to infringe on the proprietary rights of others.
The other 27 risks
  • If we are unable to protect our Internet addresses or to prevent others from using Internet addresses that are confusingly similar, our business may be adversely impacted.
  • Since most of our operations are housed two locations, we are more susceptible to a business interruption in the event of damage to, or disruptions in, our facility, particularly with respect to extreme weather events.
  • A failure or misuse of our information systems and customer-facing technology systems, including our online payment methods, could adversely affect our results of operations, expose us to third-party claims, or increase our exposure to fraud and other risks.
  • Our failure or the failure of third-party service providers to protect our websites, networks, and systems against cybersecurity incidents, or otherwise to protect our confidential information, could damage our reputation and brands and substantially harm our business, financial condition, and results of operations.
  • Our migration of data and systems to a new information technology platform may disrupt our operations.
  • Our failure to effectively adopt and use emerging technologies, including artificial intelligence and advanced data analytics, and to comply with the evolving regulatory framework governing these technologies, could adversely affect our competitive position, business, results of operations and financial condition.
  • Our marketing, e-commerce, and other business activities are subject to a variety of federal and state laws and regulations relating to privacy, data protection, marketing and advertising and consumer protection, many of which may evolve or expand beyond their current scope, and our failure to comply with this complex set of evolving laws and regulations could adversely affect our business, financial condition, and results of operations.
  • We face the risk of litigation resulting from unauthorized text messages sent in violation of the Telephone Consumer Protection Act.
  • Our operating results are difficult to predict and may fluctuate, and a portion of our sales are seasonal.
  • Uncertainties in economic conditions and their impact on consumer spending patterns could adversely impact our business, financial condition, and results of operations.
  • We may continue to seek to grow our business through acquisitions of, or investments in, new or complementary businesses, facilities, technologies, offerings, or products, or through strategic alliances, and the failure to manage these acquisitions, investments, or other strategic alliances, or to integrate them with our existing business, could have a material adverse effect on us.
  • The market for pet telemedicine is immature and uncertain. If the telemedicine market does not develop, develops more slowly than we expect, or encounters negative publicity, or if our approach does not achieve a high level of customer
  • acceptance, the growth and results of our partnership with Vetster may be adversely affected which could result in an impairment of our investment.
  • Evolving foreign trade policy by the United States or other countries or the imposition of tariffs on imported goods may affect our business.
  • Financial Risks
  • Our financial condition may currently and in the future raise substantial doubt as to our ability to continue as a going concern.
  • We are subject to payment-related risks that could increase our operating costs, expose us to fraud or theft, subject us to potential liability and potentially disrupt our business.
  • We have identified material weaknesses in our internal control over financial reporting, and management has determined that our disclosure controls and procedures were not effective as of the end of the period covered by this Annual Report on Form 10-K. Our business and share price may be adversely affected if we fail to implement and maintain effective disclosure controls and procedures and internal control over financial reporting.
  • We may face litigation and other risks as a result of the restatements as previously reported in our Annual Report on Form 10-K for the year ended March 31, 2025 and material weaknesses in our internal control over financial reporting.
  • Risks Relating to Taxes
  • Taxing authorities may successfully assert that we should have collected, or in the future should collect, sales and use, value added, or similar taxes, and any such assessments could adversely affect our business, financial condition, and results of operations.
  • Changes in tax laws or regulations in the various tax jurisdictions we are subject to could increase our cost of doing business.
  • Industry Risks
  • We face significant competition from veterinarians and online and traditional retailers, as well as challenges from strategic alliances amongst our competitors, and may not be able to compete profitably with them.
  • Product recalls and concerns regarding the safety and quality of the pet products we sell could affect our business.
  • Pandemics or other health crises, such as the possible resurgence of the COVID-19 pandemic, may adversely affect our results of operations.
  • Securities Risks
  • Our stock price fluctuates from time to time and may fall below expectations of securities analysts and investors, and could subject us to litigation, which may result in you suffering a loss on your investment.
  • We may issue additional shares of preferred stock that could defer a change of control or dilute the interests of our common shareholders. Our charter documents could defer a takeover effort which could inhibit your ability to receive an acquisition premium for your shares.
  • Actions of activist stockholders could be disruptive and costly and could adversely affect our results of operations, financial condition, and/or share price
  • Our ability to pay regular dividends to our shareholders and the amounts of any such dividends are subject to the discretion of the Board and may be limited by our financial condition, or limitations under Florida law.

Legal proceedings

For a description of our legal proceedings, see “Note 14: Commitments and Contingencies" to our consolidated financial statements, which is incorporated by reference.

The opening of Item 3, Legal Proceedings.18

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68